How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,583 results for

prostate cancer from:2010 to:2017

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer Biodegr Biodegradable spacer insertion to reduce rectal adable spacer insertion to reduce rectal to toxicity during r xicity during radiother adiotherap apy for prostate cancer y for prostate cancer Interventional procedures guidance Published: 23 August 2017 nice.org.uk/guidance/ipg590 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) Recommendations 1.1 Current evidence on the safety and efficacy of insertion of a biodegradable spacer to reduce rectal toxicity during radiotherapy for prostate cancer is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 81.2 The procedure should only be done by clinicians

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

2. Irreversible electroporation for treating prostate cancer

Irreversible electroporation for treating prostate cancer Irre Irrev versible electropor ersible electroporation for treating prostate ation for treating prostate cancer cancer Interventional procedures guidance Published: 21 December 2016 nice.org.uk/guidance/ipg572 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take (...) good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of irreversible electroporation for treating prostate cancer

2017 National Institute for Health and Clinical Excellence - Interventional Procedures

3. Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms

Padeliporfin (Tookad) - prostate cancer / Prostatic Neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 14 September 2017 EMA/644309/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report TOOKAD International non-proprietary name: padeliporfin Procedure No. EMEA/H/C/004182/0000 Note Assessment report (...) an application for marketing authorisation to the European Medicines Agency (EMA) for Tookad, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 March 2015. The applicant applied for the following indication: Tookad is indicated for the treatment of low-risk localised prostate cancer. Tookad is indicated in adult males. The legal basis for this application

2017 European Medicines Agency - EPARs

4. Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Full Text available with Trip Pro

Randomised controlled trial: Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10?years of follow-up Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you (...) prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Article Text Therapeutics/Prevention Randomised controlled trial Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up Philipp Dahm 1 , 2 , Dragan Ilic 3 , Timothy Wilt 4 , 5 Statistics from Altmetric.com Commentary

2017 Evidence-Based Medicine

5. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index

Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index Diagnosing prostate cancer: PR Diagnosing prostate cancer: PROGENSA OGENSA PCA3 assa PCA3 assay and Prostate Health Inde y and Prostate Health Index x Diagnostics guidance Published: 3 June 2015 nice.org.uk/guidance/dg17 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view (...) possible. Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index (DG17) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents 1 Recommendation 4 2 The technologies 5 3 Clinical need and practice 6 The problem addressed 6 The condition 7 The diagnostic and care pathways 7 4 The diagnostic tests 10 The interventions 10 The comparator: clinical assessment or clinical assessment plus

2015 National Institute for Health and Clinical Excellence - Diagnostics Guidance

6. The Oncentra Prostate v4.x for ultrasound-guided real-time HDR brachytherapy in men with localised prostate cancer

The Oncentra Prostate v4.x for ultrasound-guided real-time HDR brachytherapy in men with localised prostate cancer The Oncentr The Oncentra Prostate v4.x for a Prostate v4.x for ultr ultrasound-guided real-time HDR br asound-guided real-time HDR brach achyther ytherap apy y in men with localised prostate cancer in men with localised prostate cancer Medtech innovation briefing Published: 16 December 2014 nice.org.uk/guidance/mib16 pathways Summary Summary Product summary and lik Product summary (...) and likely place in ely place in ther therap apy y The Oncentra Prostate is a real-time ultrasound-guided brachytherapy system designed to treat prostate cancer. The Oncentra Prostate would be used to manage intermediate- and high-risk localised prostate cancer where radiotherapy is indicated. Effectiv Effectiveness and safety eness and safety Three small feasibility studies (n=9, 15 and 20) confirmed the system's ability to provide the prescribed radiation dose to the prostate while keeping the dose

2014 National Institute for Health and Clinical Excellence - Advice

7. Prolaris gene expression assay for assessing long-term risk of prostate cancer progression

Prolaris gene expression assay for assessing long-term risk of prostate cancer progression Prolaris gene e Prolaris gene expression assa xpression assay for assessing long- y for assessing long- term risk of prostate cancer progression term risk of prostate cancer progression Medtech innovation briefing Published: 24 May 2016 nice.org.uk/guidance/mib65 pathways Summary Summary The Prolaris test is a multi-gene assay designed to predict the aggressiveness (growth and spread) of prostate cancer (...) cancer. The Prolaris score is combined with patient and tumour information to generate either the 10-year prostate cancer-specific mortality risk (from biopsy samples) or the 10-year risk of biochemical recurrence (from prostatectomy specimens), which may indicate the need for further treatment. The Prolaris score would be used in addition to existing risk stratification information and is likely to be used in place of available nomograms, where these are used. Effectiv Effectiveness and safety eness

2016 National Institute for Health and Clinical Excellence - Advice

8. Hormone-sensitive metastatic prostate cancer: docetaxel

Hormone-sensitive metastatic prostate cancer: docetaxel Hormone-sensitiv Hormone-sensitive metastatic prostate cancer: e metastatic prostate cancer: docetax docetaxel el Evidence summary Published: 5 January 2016 nice.org.uk/guidance/esuom50 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in January 2016. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up (...) -to-date information. Summary Randomised controlled trial (RCT) data suggest that docetaxel improves overall survival and time to disease progression in men with hormone-sensitive metastatic prostate cancer. Two RCTs found that, compared with androgen deprivation therapy (ADT) alone, docetaxel combined with ADT statistically significantly improved overall survival by around 10–15 months in this population. No statistically significant difference was seen between the groups in another, smaller RCT. Time

2016 National Institute for Health and Clinical Excellence - Advice

9. Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

Brachytherapy for Patients with Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Genitourinary Cancer | ASCO Search form Search ASCO Family of Sites ASCOconnection.org features blogs from ASCO members, the online version of the membership magazine, a discussion area, working groups, and links to the ASCO Membership Directory, Career Center, and Volunteer Portal. ASCO’s growing roster of cutting-edge journals serves readers as the most credible (...) , authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. ASCO Practice Central helps oncology professionals navigate a complicated and ever-changing practice environment—while providing high-quality patient care. ASCO University serves as a comprehensive eLearning and mobile learning center that supports lifelong learning for physicians, advanced practice providers, and patient educators

2017 Cancer Care Ontario

10. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel Cabazitax Cabazitaxel for hormone-relapsed el for hormone-relapsed metastatic prostate cancer treated with metastatic prostate cancer treated with docetax docetaxel el T echnology appraisal guidance Published: 25 May 2016 nice.org.uk/guidance/ta391 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) , to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Degarelix for treating advanced hormone-dependent prostate cancer

Degarelix for treating advanced hormone-dependent prostate cancer Degarelix for treating advanced Degarelix for treating advanced hormone-dependent prostate cancer hormone-dependent prostate cancer T echnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta404 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Degarelix for treating advanced hormone-dependent prostate cancer (TA404) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 39Contents Contents 1 Recommendations 4 2 The technology 5 3

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

12. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Radium-223 dichloride for treating Radium-223 dichloride for treating hormone-relapsed prostate cancer with hormone-relapsed prostate cancer with bone metastases bone metastases T echnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta412 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our (...) unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

13. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Abir Abiraterone for treating metastatic aterone for treating metastatic hormone-relapsed prostate cancer hormone-relapsed prostate cancer before chemother before chemotherap apy is indicated y is indicated T echnology appraisal guidance Published: 27 April 2016 nice.org.uk/guidance/ta387 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387) © NICE 2019. All rights reserved

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

14. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Enzalutamide for treating metastatic Enzalutamide for treating metastatic hormone-relapsed prostate cancer hormone-relapsed prostate cancer before chemother before chemotherap apy is indicated y is indicated T echnology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta377 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377) © NICE 2019. All rights reserved

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

15. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases

Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | Guidance | NICE Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Technology appraisal guidance [TA376] Published date: 27 January 2016 Guidance This guidance has been updated and replaced by . Explore © NICE [year]. All rights reserved. Subject to .

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

16. Prostate-Specific Antigen?Based Population Screening for Prostate Cancer

Prostate-Specific Antigen?Based Population Screening for Prostate Cancer PSA-Based Population Screening for Prostate Cancer: OHTAC Recommendation. May 2015; pp. 1–5 Prostate-Specific Antigen (PSA)–Based Population Screening for Prostate Cancer: OHTAC Recommendation HEALTH QUALITY ONTARIO ONTARIO HEALTH TECHNOLOGY ADVISORY COMMITTEE RECOMMENDATION OHTAC recommends against the introduction of a formal, population-based PSA screening program for prostate cancer in Ontario. BACKGROUND Prostate (...) cancer (PC) is the most commonly diagnosed non-cutaneous cancer in men and their second or third most common cause of cancer-related deaths. Prostate cancer is a heterogeneous disease with a variable natural history ranging from low-risk tumours (unlikely to threaten men’s quality or length of life) to highly aggressive forms. The etiology of PC is largely unknown and the established risk factors—older age, ethnicity, and family history—explain only a fraction of variation in disease occurrence

2015 Health Quality Ontario

17. Prostate cancer: diagnosis and management

Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management Clinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Prostate cancer: diagnosis and management (CG175) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 45Contents Contents Introduction 5 Drug

2014 National Institute for Health and Clinical Excellence - Clinical Guidelines

18. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update.

Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. | National Guideline Clearinghouse success fail JUN Jul 10 2017 2018 2019 03 Oct 2017 - 14 Jun 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue (...) NGC:011222 2017 May 20 NEATS Assessment Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology/Cancer Care Ontario joint guideline update. J Clin Oncol. 2017 May 20;35(15):1737-43. [22 references] This is the current release

2017 National Guideline Clearinghouse (partial archive)

19. Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management

Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management | Cancer Care Ontario Google Tag Manager You are using an outdated browser. We suggest you update your browser for a better experience. for update. Browse Guidelines Browse Pathway Maps Sort by You are here / / Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management Guidelines & Advice (...) Guideline for Optimization of Surgical and Pathological Quality Performance for Radical Prostatectomy in Prostate Cancer Management english Version: 2 ID: 17-3 Oct 2017 Type of Content: Guidelines & Advice, Clinical Document Status: Current Authors: J. Chin, J. Srigley, L.A. Mayhew, R.B. Rumble, C. Crossley, A. Hunter, N. Fleshner, B. Bora, R. McLeod, S. McNair, B. Langer, A. Evans, Prostate Cancer Surgery and Pathology Expert Panel Guideline Objective The objective of this document is to provide

2017 Cancer Care Ontario

20. MR guided biopsy procedures for diagnosis of prostate cancer

MR guided biopsy procedures for diagnosis of prostate cancer 1 Public Summary Document Application No. 1424 – MR guided biopsy procedures for diagnosis of prostate cancer Applicant: Australian and New Zealand Association of Urological Surgeons Date of MSAC consideration: MSAC 69 th Meeting, 6-7 April 2017 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting two new Medicare Benefits (...) Schedule (MBS) listings for MR- guided prostate biopsy in men with a high or concerning Prostate Specific Antigen (PSA) and under suspicion of harbouring prostate cancer was received from the Australian and New Zealand Association of Urological Surgeons (ANZAUS) and the Australian Diagnostic Imaging Association (ADIA) by the Department of Health (the Department). 2. MSAC’s advice to the Minister After considering the strength of the available evidence presented in relation to comparative safety

2017 Medical Services Advisory Committee

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>